Allogene Therapeutics Conference Call - ALLOGENE THERAPEUTICS INC

Financial Performance:

• No specific revenue, earnings, or cash flow metrics disclosed as the company is in clinical development (Phase 1).
• Focus remains on the execution of the Resolution Trial (Phase 1) rather than commercial financials.
• No mention of debt levels or deferred revenue in this transcript.

Guidance and Future Outlook:

• Plans to continue dose escalation and initiate dose expansion cohorts in 2024/2025.
• Aiming to define a Phase 2 regimen based on emerging safety and efficacy data, potentially shifting from basket design to focused indications (e.g., scleroderma).
• Expectations to provide updates on durability of response, optimal lymphodepletion regimens, and the role of peripheral B-cell depletion as follow-up increases.
• Long-term goal to establish a practical, accessible therapy that may not require chemotherapy-based lymphodepletion.

Business Segments and Product Lines:

• Product: ALLO329, an allogeneic CAR-T cell therapy targeting both CD19 (on B cells) and CD70 (on activated T cells) using "DAGGER" technology to reduce rejection.
• Trial: The Resolution Trial (Phase 1) evaluating ALLO329 in patients with diffuse cutaneous scleroderma, lupus, and inflammatory myositis.
• Key Findings: 18 patients enrolled to date; efficacy data presented on 10 patients with scleroderma.
• Clinical Outcomes: 8 of 10 patients achieved a ≥5-point reduction in Modified Rodnan Skin Score (MRSS) with several seeing >10-point reductions; improvements observed as early as Day 14.
• De-conditioning: Demonstrated efficacy in patients receiving no lymphodepletion chemotherapy (No LD), Cytoxan (Cy), and Fludarabine/Cytoxan (Flu/Cy).

Market and Competitive Landscape:

• Indication: Targeting rare, complex autoimmune diseases with high unmet need, specifically scleroderma (systemic sclerosis) where few treatments exist for skin involvement.
• Differentiation: First allogeneic CAR-T to target CD19/CD70, designed to eliminate or reduce chemotherapy dependency, contrasting with autologous CAR-T approaches in oncology or other autoimmune trials.
• Market Position: Addresses a critical gap in treating treatment-refractory scleroderma, aiming for a potential "one-time" or finite treatment duration compared to chronic immunosuppressive therapy.
• Competitive Context: References recent industry-wide pauses due to high-grade toxicities in other cell therapies, positioning ALLO329's safety profile as a key competitive advantage.

Risks and Challenges:

• Durability: Current data is early (median follow-up ~6 months); long-term durability of response remains to be confirmed.
• Patient Variability: Some patients showed initial response followed by stabilization or slight progression (e.g., Patient 6), indicating a need to understand resistance mechanisms.
• Immune Risks: Concerns regarding prolonged immunosuppression, opportunistic infections, and the potential need for re-treatment if B-cells repopulate.
• Trial Design: Uncertainty remains regarding the optimal lymphodepletion regimen and the specific biomarkers required for efficacy (specifically challenging the paradigm of complete B-cell aplasia).

Management Commentary and Tone:

• Tone: Highly confident, optimistic, and patient-centric, emphasizing safety and the reduction of treatment burden.
• Strategic Philosophy: Management emphasizes moving away from repurposing oncology protocols, prioritizing safety and practicality for chronic disease management.
• Investor Relations: Management is actively evaluating the path to Phase 2, suggesting a transition to expanded cohorts soon to support a registration trial design.
• Credibility: Strong endorsement from Dr. Vivek Nagarajah (Mayo Clinic), highlighting the clinical significance of rapid skin improvement and the potential for outpatient administration.

Analyst Questions and Answers:

• Immune Reset (UBS): Management questioned the necessity of complete B-cell aplasia for efficacy, suggesting the "reset" may involve niche targeting (tissue-based) via CD70 rather than peripheral blood depletion.
• Trial Expansion (Piper Sandler): Confirmed internal discussions are underway to move from pure dose escalation to cohort expansion for Phase 2 readiness; noted GI improvements (esophageal dysmotility) in some patients but emphasized the need for more data.
• Durability (TD Cowen): Dr. Nagarajah expressed cautious optimism, noting that while zero skin score is ideal, meaningful improvement in symptoms and function is the primary clinical metric.
• Lung Involvement (Canaccord): Lung function appears stable in patients with ILD, though skin response is faster; data too early to claim lung efficacy.
• Kinetics & Persistence (Goldman Sachs): Clarified that long-term CAR-T persistence is not the goal; the aim is to alter immunobiology temporarily. CD70 is hypothesized to act at tissue sites to drive efficacy without indefinite cell persistence.
• Worsening Patient (Jefferies): Acknowledged a patient with a transient response followed by worsening; investigation into mechanisms of resistance is ongoing.

Other Key Points:

• Safety Profile: No Grade 3+ CRS, no ICANS, no GvHD, and no dose-limiting toxicities observed in the first 18 patients.
• Immunosuppression: 9 of 10 efficacy patients successfully discontinued background immunosuppressive therapy after ALLO329 administration.
• Biomarker Insights: Data suggests that deep peripheral B-cell depletion is not strictly required for clinical response, challenging industry standards and potentially reducing infection risk.
• Clinical Impact: Reported improvements in physical function (e.g., walking ability, hand mobility) and reduction of digital ulcers, which are not fully captured by standard scoring alone.